Although essential for immune response, excessive and/or prolonged recruitment of leukocytes to the site of insult contributes to the development of chronic inflammatory pathologies, such as autoimmune, cardiovascular, and skin diseases, or cancer. Chronic inflammatory diseases are a major burden for society today, and fighting against them represents a WHO (World Health Organization) strategic priority. Currently, most available treatments modulating inflammation are non-steroidal and steroidal drugs that oppose the concept of specific neutralization of inflammation in a tissue or an organ. Even the new anti-inflammatory treatments provided by the biologics have harmful effects. Despite their efficiency, most of these molecules treat the organism non-specifically, frequently leading to numerous side effects such as significantly lowering innate and cell-mediated immunity.
Targeting a particular signaling pathway, cell type, tissue, or organ without increasing susceptibility to infections or other diseases secondary to a treatment, is thus of great interest in the search of novel treatments to control undesirable inflammation. In the quest of controlling this undesirable inflammation with reduced side effects, small peptides are promising tools as they have be shown to present high specificity (especially peptides with allosteric properties) and binding affinity, reduced immunogenicity and toxicity, excellent tissue permeability, and for some, dual activities, such as anti-inflammatory and antimicrobial activities. The source of therapeutic peptides is almost inexhaustible as they can have natural or designed origins. The goal of this Research Topic is to highlight advantages in the use of small peptides regulating inflammation in the treatment but also in the diagnosis of inflammatory diseases.
Manuscripts describing original research, commentaries, methods, hypothesis and theory as well as reviews and mini-reviews, focusing on one of the following aspects (but not exclusively) are welcome:
• Interest/use of labeled peptides in the diagnosis of inflammatory diseases
• Small peptides with dual biological activities in the treatment of inflammatory diseases
• Original peptides that target a particular cell type or organ implicated in inflammation
• Animal models of Inflammatory diseases for the in vivo validation of a peptide
• Interest of the use of cell penetrating peptides or short interfering peptides in inflammatory diseases
• Anti-inflammatory peptides in pre-clinical or clinical trials
• Designing peptidomimetics for inflammatory processes
• Peptides with allosteric properties: examples and benefits in the treatment of inflammatory diseases
Although essential for immune response, excessive and/or prolonged recruitment of leukocytes to the site of insult contributes to the development of chronic inflammatory pathologies, such as autoimmune, cardiovascular, and skin diseases, or cancer. Chronic inflammatory diseases are a major burden for society today, and fighting against them represents a WHO (World Health Organization) strategic priority. Currently, most available treatments modulating inflammation are non-steroidal and steroidal drugs that oppose the concept of specific neutralization of inflammation in a tissue or an organ. Even the new anti-inflammatory treatments provided by the biologics have harmful effects. Despite their efficiency, most of these molecules treat the organism non-specifically, frequently leading to numerous side effects such as significantly lowering innate and cell-mediated immunity.
Targeting a particular signaling pathway, cell type, tissue, or organ without increasing susceptibility to infections or other diseases secondary to a treatment, is thus of great interest in the search of novel treatments to control undesirable inflammation. In the quest of controlling this undesirable inflammation with reduced side effects, small peptides are promising tools as they have be shown to present high specificity (especially peptides with allosteric properties) and binding affinity, reduced immunogenicity and toxicity, excellent tissue permeability, and for some, dual activities, such as anti-inflammatory and antimicrobial activities. The source of therapeutic peptides is almost inexhaustible as they can have natural or designed origins. The goal of this Research Topic is to highlight advantages in the use of small peptides regulating inflammation in the treatment but also in the diagnosis of inflammatory diseases.
Manuscripts describing original research, commentaries, methods, hypothesis and theory as well as reviews and mini-reviews, focusing on one of the following aspects (but not exclusively) are welcome:
• Interest/use of labeled peptides in the diagnosis of inflammatory diseases
• Small peptides with dual biological activities in the treatment of inflammatory diseases
• Original peptides that target a particular cell type or organ implicated in inflammation
• Animal models of Inflammatory diseases for the in vivo validation of a peptide
• Interest of the use of cell penetrating peptides or short interfering peptides in inflammatory diseases
• Anti-inflammatory peptides in pre-clinical or clinical trials
• Designing peptidomimetics for inflammatory processes
• Peptides with allosteric properties: examples and benefits in the treatment of inflammatory diseases